Cotización Entero Therapeutics - ENTO

	Precios en Tiempo Real	Nivel 2
Forex

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

0.463

Postura de Compra

0.42

Postura de Venta

0.441

Volume Operado de la Acción

20,642

0.4124 Rango del Día 0.477025

0.185 Rango de 52 semanas 3.16

Precio Anterior

0.4652

Precio de Apertura

0.4507

Hora

500

0.463

(formt)

Última hora de negociación

16:42:28

Volumen promedio (3 m)

410,455

Volumen financiero

US$ 9,353

Precio Promedio Ponderado

0.4531

Form 8-K - Current report

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0.083	21.8421052632	0.38	0.49	0.38	50212	0.43788031	CS
4	-0.1271	-21.5387222505	0.5901	0.7208	0.38	173593	0.58636972	CS
12	0.0378	8.88993414864	0.4252	0.8655	0.28	410455	0.56491337	CS
26	-2.377	-83.6971830986	2.84	2.8599	0.185	471483	0.47565264	CS
52	-2.497	-84.3581081081	2.96	3.16	0.185	450970	0.47879628	CS
156	-2.497	-84.3581081081	2.96	3.16	0.185	450970	0.47879628	CS
260	-2.497	-84.3581081081	2.96	3.16	0.185	450970	0.47879628	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
BMRABiomerica Inc	US$ 0.4582 (42.25%)	9.75M
BSLKBolt Projects Holdings Inc	US$ 0.35 (18.24%)	70.76k
ONCOOnconetix Inc	US$ 0.77 (16.31%)	34.05k
MOBXMobix Labs Inc	US$ 1.4099 (14.63%)	272.52k
BOCNBlue Ocean Acquisition Corporation	US$ 15.51 (12.80%)	9.85k
APLTApplied Therapeutics Inc	US$ 1.93 (-77.48%)	8.62M
TOIIWOncology Institute Inc	US$ 0.0135 (-28.57%)	5.82k
CMAXCareMax Inc	US$ 0.34 (-19.34%)	458.69k
TCBPTC BioPharm Holdings PLC	US$ 0.50 (-16.67%)	158.76k
IDAIT Stamp Inc	US$ 0.716 (-14.76%)	9.35M
CRKNCrown Electrokinetics Corporation	US$ 0.3085 (10.53%)	11.85M
BMRABiomerica Inc	US$ 0.4582 (42.25%)	9.75M
IDAIT Stamp Inc	US$ 0.716 (-14.76%)	9.35M
PGHLPrimega Group Holdings Ltd	US$ 1.8699 (13.33%)	9.24M
APLTApplied Therapeutics Inc	US$ 1.93 (-77.48%)	8.62M